Significant Agreements - Novo Nordisk Share Purchase Agreement (Details) - Novo Nordisk - USD ($) |
1 Months Ended | 3 Months Ended | 6 Months Ended | ||||
|---|---|---|---|---|---|---|---|
Jul. 08, 2021 |
Dec. 31, 2022 |
Jun. 30, 2025 |
Jun. 30, 2024 |
Jun. 30, 2025 |
Jun. 30, 2024 |
Dec. 31, 2024 |
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||||
| Share Purchase Agreement, Upfront Payment | $ 60,000,000.0 | ||||||
| Share Purchase Agreement, Potential Payment Upon Achievement of Development and Sales Milestones | $ 1,130,000,000 | $ 1,130,000,000 | |||||
| Revenue from License and Intellectual Property, Share Purchase Agreement | 0 | $ 0 | 0 | $ 0 | |||
| Milestone achievement, Clinical milestone | $ 40,000,000.0 | ||||||
| Accounts Receivable, after Allowance for Credit Loss | $ 0 | $ 0 | $ 0 | ||||
| Transition services | |||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||||
| Revenue from License and Intellectual Property, Share Purchase Agreement | $ 700,000 | ||||||